Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan's Botox Holds Its Own In Migraine, Despite CGRP Competition

Executive Summary

In the third quarter, generics of dry eye drug Restasis did not emerge as expected and Botox enjoyed double digit sales for therapeutic indications in the US, despite the entry of new competition in migraine treatment.

Advertisement

Related Content

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun
Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?
Allergan Buys Bonti, Releases New Data In Defense Of 'Iconic' Botox Brand
Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Allergan Fights Generic Headwinds, Activist Investors
Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD
No Fire Sale: Allergan May Sell Women’s Health, Infectious Disease Units
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel